Yazar "Ebinc, Fatma Ayerden" seçeneğine göre listele
Listeleniyor 1 - 5 / 5
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Frequency of microalbuminuria and its relationship with other atherosclerotic risk factors in nondiabetic hypertensive patients(Turkish Soc Cardiology, 2007) Özkurt, Zübeyde Nur; Ebinc, Fatma Ayerden; Keles, Hatice; Ebinc, Haksun; Gueliter, Sefa…Öğe LIPID PEROXIDATION AND THE ANTIOXIDANT CAPACITY OF DIALYSIS PATIENTS: The Effects of a Single Hemodialysis Session with Different Dialysis Membranes(Gazi Univ, Fac Med, 2008) Derici, Ulver; Ebinc, Fatma Ayerden; Yilmaz, Murat; Kulaksizoglu, Sevsen; Arinsoy, Turgay; Sindel, SukrurObjective: To estimate lipid peroxidation and the antioxidant defense capacity of dialysis patients and the effects of different types of dialysis membranes on these parameters. Methods: Fifty-four dialysis patients and 30 healthy controls were included in this study. Ten of the dialysis patients were on continuous ambulatory peritoneal dialysis treatment and the rest were on hemodialysis with either polycarbonate membrane (n=10) or hemophan membrane (n=34). Polycarbonate membranes were switched with a vitamin E-coated dialyzer in the subsequent dialysis session. Total antioxidant status and malondialdehyde levels were studied to determine the antioxidant defense capacity and lipid peroxidation, respectively, before and after the dialysis session. Results: Plasma total antioxidant status levels were lower (1.51 +/- 0.2 mmol/l vs. 1.75 +/- 0.20 mmol/l p<0.05) and malondialdehyde levels were higher (2.2 +/- 1.17 nmol/ml vs. 0.60 +/- 0.20 nmol/ml p<0.05) in all dialysis patients compared to the control group. After one hemodialysis session, there were no significant alterations in parameters for either type of dialysis membrane. Conclusion: All dialysis patients have an increased oxidative status. A single hemodialysis session with different dialysis membranes does not seem to significantly change the oxidant or antioxidant levels.Öğe The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients(Taylor & Francis Ltd, 2008) Ebinc, Fatma Ayerden; Erten, Yasemin; Ebinc, Haksun; Pasaoglu, Hatice; Demirtas, Canan; Tacoy, Guelten; Sindel, SuekrueAsymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial-based nitric oxide synthase. Its level is increased by end stage renal disease. However, most studies showing an increase in ADMA in dialysis patients have focused on hemodialysis. Results with peritoneal dialysis patients have been more inconclusive. Recent studies suggest that ADMA may be a new cardiovascular risk factor. The aim of the present study was to evaluate the relationship between ADMA levels, residual renal function, and left ventricular hypertrophy in peritoneal dialysis patients. Serum ADMA measurements and echocardiographic evaluations were performed in 54 peritoneal dialysis patients and 26 healthy volunteers. Residual renal function was measured in peritoneal dialysis patients by urea clearance from a urine collection. Thirty-two of the 54 peritoneal dialysis patients had residual renal function. ADMA levels of the peritoneal dialysis group were found to be significantly higher than those of healthy individuals (p = 0.03). Within the peritoneal dialysis group, ADMA levels of patients with residual renal function were significantly lower than those without residual renal function (p = 0.01), though they were still higher than the ADMA levels of the control group (p=0.04). Serum levels of ADMA were positively correlated with left ventricular mass index (r = 0.29, p = 0.01) and negatively correlated with early mitral inflow velocity (Em) (r = -0.28, p = 0.01), Em/Late mitral inflow velocity (Am) (r = -0,32, p = 0.00), and isovolumetric relaxation time (r = -0.30, p = 0.01). In conclusion, increased ADMA levels seem to be associated with left ventricular hypertrophy in peritoneal dialysis patients, and residual renal function may lead to a reduction of serum ADMA levels.Öğe The relationship between adiponectin levels and proinflammatory cytokines and left ventricular mass in dialysis patients(Springer Heidelberg, 2009) Ebinc, Fatma Ayerden; Ebinc, Haksun; Derici, Ülver; Aral, Arzu; Aybay, Cemalettin; Tacoy, Gülten; Sindel, ŞükrüIntroduction: Adiponectin is increased in end-stage renal disease. However, efforts to clarify the cause of that increase and its clinical effects have been inconclusive. The aim of this study was to compare serum adiponectin levels of dialysis patients against healthy individuals and evaluate the relationship among adiponectin levels, IL-6, TNF-alpha and left ventricular mass index (LVMI). Methods: Adiponectin, IL-6 and TNF-a measurements and echocardiographic evaluations were performed in 36 hemodialysis, 30 continuous ambulatory peritoneal dialysis (CAPD) patients and 22 healthy volunteers. Adiponectin, IL-6 and TNF-alpha levels were measured by ELISA. Results: Adiponectin was found to be higher in hemodialysis (52.78 +/- 18.01 ng/mL) and CAPD (52.96 +/- 17.53 ng/mL) groups than controls (28.36 +/- 13.20 ng/ mL; p = 0.0003, p = 0.0003, respectively). No difference was observed between the hemodialysis and CAPD groups. Adiponectin was positively correlated with IL-6 (r = 0.293, p = 0.02), TNF-alpha (r = 0.458, p = 0.0003) and LVMI (r = 0.283, p = 0.02). In the partial correlation analysis, by controlling for body mass index, the correlation between adiponectin and TNF-alpha (r = 0.466, p = 0.0003) persisted. When IL- 6 was controlled with TNF- a, the relation between adiponectin and LVMI disappeared (r = 0.145, p = 0.30). In the linear regression analysis, with adiponectin as the dependent variable, and IL-6, TNF-alpha and body mass index as independent variables, a significant relationship was found between adiponectin and TNF-alpha (beta = 0.488, p = 0.001). Conclusions: Increased adiponectin seems to be associated with increased proinflammatory cytokines in dialysis patients, and this relationship suggests adiponectin may have a role in the development of left ventricular hypertrophy.Öğe The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients(Taylor & Francis Ltd, 2008) Erten, Yasemin; Ebinc, Fatma Ayerden; Ebinc, Haksun; Pasaoglu, Hatice; Demirtas, Canan; Tacoy, Guelten; Sindel, SuekrueVisfatin was recently defined as an adipocytokine; however, the pathophysiological role of visfatin is not completely understood. A few studies suggest that visfatin may be a new proinflammatory adipocytokine. The aim of the present study was to compare serum visfatin levels between hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) patients and evaluate the relationship between visfatin levels to IL-6, TNF-alpha, and left ventricular hypertrophy. Serum visfatin, IL-6, and TNF-alpha levels were measured by using the ELISA method, and echocardiographic evaluations were performed in 31 hemodialysis patients, 30 CAPD patients, and 21 healthy volunteers. Serum visfatin levels were higher in the CAPD group (265.27 +/- 387.86 ng/mL) than hemodialysis (97.68 +/- 244.96 ng/mL,) and control (41.33 +/- 48.87 ng/mL) groups (p = 0.04, p = 0.01, respectively). No significant difference was observed between the hemodialysis and control groups. In univariate analysis, visfatin levels were positively correlated with IL-6 (r = 0.24, p = 0.03), TNF-alpha (r = 0.34, p = 0.002), and BMI (r = 0.26, p = 0.03) and negatively correlated with some left ventricular diastolic parameters [ Em and Em/Am (r =-0.305, p = 0.01), (r =-0.251, p = 0.03), respectively]. No relationship was found between visfatin and left ventricular mass index. In the linear regression analysis, visfatin levels independently related with TNF-((beta = 0.369, p = 0.001) and IL-6 (beta = 0.284, p = 0.015). This study has found significantly higher levels of serum visfatin in CAPD patients when compared to healthy individuals. Increased visfatin levels seem to associate with proinflammatory cytokines such as IL-6 or TNF-alpha. As for the effects of on left ventricular structure and functions, visfatin might have negative effects on left ventricular diastolic function parameters but have no effects on left ventricular mass index.
